HMMvar-func: A new method for predicting the functional outcome of genetic variants

BMC Bioinformatics

Volumn 16, Issue 1, 2015, Pages

  Liu, Mingming ^a   Watson, Layne T ^a,b   Zhang, Liqing ^a  

^a Virginia Polytechnic Institute and State University   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Functional outcome; Genetic variants; Hidden Markov model

Indexed keywords

DISEASES; FORECASTING; MARKOV PROCESSES; ONCOGENIC VIRUSES; PROTEINS; TRELLIS CODES;

FINE-GRAINED PREDICTIONS; FUNCTIONAL OUTCOME; GENETIC VARIANTS; MOLECULAR MECHANISM; NEW FUNCTIONS; THYROID STIMULATING HORMONES; TUMOR SUPPRESSOR GENES;

HIDDEN MARKOV MODELS;

THYROTROPIN RECEPTOR;

BIOLOGY; COMPUTER INTERFACE; GENETIC VARIATION; GENETICS; HUMAN; INTERNET; MARKOV CHAIN; MUTATION; NEOPLASM; PATHOLOGY; PROCEDURES;

COMPUTATIONAL BIOLOGY; GENETIC VARIATION; HUMANS; INTERNET; MARKOV CHAINS; MUTATION; NEOPLASMS; RECEPTORS, THYROTROPIN; USER-COMPUTER INTERFACE;

EID: 84945566529     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/s12859-015-0781-z     Document Type: Article

References (32)

1. Pauline C, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2011; 11:863-74.
2. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002; 30:3894-900.
3. Choi Y, Sims G, Murphy S. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE. 2012; 7:10.
4. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014; 46:310-5.
5. Cooper G, Shendure J. Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data. Nat Rev Genet. 2011; 12:628-40.
6. Asthana S, Roytberg M, Stamatoyannopoulos J. Analysis of sequence conservation at nucleotide resolution. PLOS Comput Biol. 2007; 3:254.
7. Hu J, Pauline C. Predicting the effects of frame shifting indels. Genome Biol. 2012; 13:2.
8. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 2011; 39:118.
9. Emma RC, John JO, Orla MS. BRAF V600E: Implication for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011; 10:385.
10. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of V600 mutation in melanoma. J Transi Med. 2012; 10:85.
11. Rodriguez-Escudero I, Oliver MD, Andres-Pons A, Molina M, Cid VJ, Pulido R. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum Mol Genet. 2011; 20(21):4132-42.
12. Lee W, Zhang Y, Mukhyala K, Lazarus RA, Zhang Z. Bi-directional SIFT predicts a subset of activating mutations. PLoS ONE. 2009; 4:8311.
13. Ng S, Collisson EA, Sokolov A, Goldstein T, Gonzalez-Perez A, Lopez-Bigas N, et al. PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis. Bioinforma. 2012; 28:640-6.
14. Liu M, Watson LT, Zhang L. Quantitative prediction of the effect of genetic variation using hidden Markov models. BMC Bioinforma. 2014; 15:5.
15. TSH Receptor Mutation Database II. http://endokrinologie.uniklinikum-leipzig.de/tsh/
16. Tuna M, Amos IC. Activating mutations and targeted therapy in cancer In: Cooper D, editor. Mutations in Human Genetic Disease. New York: InTech: 2012.
17. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al.Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997; 25(17):3389-407.
18. Suzek BE, Huang H, McGarvey P, Mazumder R, Wu CH. UniRef: comprehensive and non-redundant UniProt reference clusters. Bioinforma. 2007; 23(10):1282-8.
19. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004; 32:1792-7.
20. Reva B, Antipin Y, Sander C. Determinants of protein function revealed by combinatorial entropy optimization. Bioinforma. 2007; 23(10):1282-8.
21. Duprez L, Parma J, Sande JV, Rodien P, Dumont JE, Vassart G, et al.TSH receptor mutations and thyroid disease. Trends Endocrinol Metab. 1998; 9(4):133-40.
22. Liu M, Watson LT, Zhang L. Classification of mutations by functional impact type: Gain of function, loss of function, and switch of function In: Basu M, Pan Y, Wang J, editors. Bioinformatics Research and Applications - 10th International Symposium, ISBRA. Lecture Notes in Computer Science, vol. 8492. Switzerland: Springer International Publishing: 2014. p. 236-42.
23. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462:739-44.
24. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview version 2 - a multiple sequence alignment editor and analysis workbench. Bioinforma. 2009; 25(9):1189-91.
25. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, et al.Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005; 65(17):7591-95.
26. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al.The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268-74.
27. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, et al.Distinct gene mutation profile among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 2010; 121(1):53-64.
28. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366(1):2-16.
29. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:9-15.
30. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949-54.
31. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, et al.BRAF and KRAS mutations in stomach cancer. Oncogene. 2003; 22:6942-5.
32. Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M, Fujinaga K. The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. Oncogene. 1996; 12(11):2361-7.